Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Malard F et al. Cancer Treat Rev. 2016 Nov 15;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. [Epub ahead of print].

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P et al. Ann Oncol. 2016 Nov 17. pii: mdw606. [Epub ahead of print].

Aging, ‘Treating the Older Patient’.
Rosko A et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30485-2. doi: 10.1016/j.bbmt.2016.11.007. [Epub ahead of print].

Panobinostat in multiple myeloma.
Gertz MA. Lancet Haematol. 2016 Nov 11. pii: S2352-3026(16)30169-7. doi: 10.1016/S2352-3026(16)30169-7. [Epub ahead of print].

Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A et al. Blood Cells Mol Dis. 2016 Nov 10;62:49-63. doi: 10.1016/j.bcmd.2016.11.001. [Epub ahead of print].

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP et al. Clin Pharmacol Ther. 2016 Nov 2. doi: 10.1002/cpt.550. [Epub ahead of print].

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study.
Chari A et al. BMC Cancer. 2016 Nov 22;16(1):912.

Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C. Pharmacotherapy. 2016 Nov 21. doi: 10.1002/phar.1871. [Epub ahead of print].

HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?
Maksimovic-Ivanic D et al. Int J Cancer. 2016 Nov 21. doi: 10.1002/ijc.30529. [Epub ahead of print].

Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
Luo J et al. Eur J Cancer. 2016 Nov 17;70:22-33. doi: 10.1016/j.ejca.2016.10.018. [Epub ahead of print].

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Zhang K et al. Oncotarget. 2016 Nov 11. doi: 10.18632/oncotarget.13314. [Epub ahead of print].

Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
van de Velde H et al. Eur J Haematol. 2016 Nov 16. doi: 10.1111/ejh.12829. [Epub ahead of print].

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K et al. BMC Med Res Methodol. 2016 Nov 9;16(1):151.

Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma.
Pezzi A et al. BMC Med Res Methodol. 2016 Nov 9;16(1):150.

Multiple Myeloma in an 8-Year-Old Child With HIV Infection.
Radhakrishnan V et al. J Pediatr Hematol Oncol. 2016 Nov 4. [Epub ahead of print].

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR et al. Bone Marrow Transplant. 2016 Nov 7. doi: 10.1038/bmt.2016.258. [Epub ahead of print].

Observational study of multiple myeloma in Latin America.
Hungria VT et al. Ann Hematol. 2016 Nov 5. [Epub ahead of print].